Europe’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats
Brussels, Belgium – 18 August 2020 – CARE (Corona Accelerated R&D in Europe) a new consortium supported by the Innovative Medicines Initiative (IMI) public-private partnership announced its launch today to accelerate the discovery and development of urgently needed medicines to treat SARS-CoV-2, the virus that causes COVID-19. With a grant totaling € 77.7 million, CARE is funded by cash contributions from the European Union (EU) and cash and in-kind contributions from eleven European Federation of Pharmaceutical Industries and Associations (EFPIA) companies and three IMI-Associated Partners. CARE is a five-year project bringing together 37 partners from Belgium, China, Denmark, France, Germany, the Netherlands, Poland, Spain, Switzerland, the UK and the US, and is led by VRI-Inserm (French National Institute of Health and Medical Research, Paris, France), Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Beerse, Belgium), and Takeda Pharmaceuticals International AG, (Zurich, Switzerland).
Dr Jacky Vonderscher, ENYO Pharma’s CEO said : « COVID-19 is a kind of wake-up call for the humanity. Thanks to IMI public-private partnership, the CARE consortium is a unique opportunity for a company like ENYO to contribute with our drugs and our knowledge to the fight against this virus and future ones potentially even more dangerous.”Télécharger le communiquer complet (PDF)
À lire dans 'Press releases'
- ENYO PHARMA ANNONCE PLUSIEURS PRESENTATIONS DE DONNEES SUR EYP001 LORS DE LA CONFERENCE AASLD
- ENYO PHARMA DÉMÉNAGE SON SIEGE SOCIAL
- ENYO PHARMA ANNONCE LE RECRUTEMENT D’UN NOUVEAU DIRECTEUR FINANCIER ET ACTUALISE SON PIPELINE CLINIQUE
- ENYO Pharma annonce le succès de sa phase Ib avec son agoniste de FXR EYP001 et le début de ses études de phase II dans deux indications, NASH et HBV
- ENYO Pharma réalise une levée de fonds de 40 millions d’euros lors d’une Série B